0

Myeloid Derived Suppressor cells-An Overview of Combat Strategies to Increase Immunotherapy Efficacy

Oana Draghiciu, Joyce Lubbers, Hans W Nijman, Toos Daemen

Oncoimmunology. 2015 Feb 3;4(1):e954829.

PMID: 25949858

Abstract:

Myeloid-derived suppressor cells (MDSCs) contribute to tumor-mediated immune escape and negatively correlate with overall survival of cancer patients. Nowadays, a variety of methods to target MDSCs are being investigated. Based on the intervention stage of MDSCs, namely development, expansion and activation, function and turnover, these methods can be divided into: (I) prevention or differentiation to mature cells, (II) blockade of MDSC expansion and activation, (III) inhibition of MDSC suppressive activity or (IV) depletion of intratumoral MDSCs. This review describes effective mono- or multimodal-therapies that target MDSCs for the benefit of cancer treatment.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
LS7931257 1-(3-Methylbutyl)-1H-pyrazole-4-boronic acid 1-(3-Methylbutyl)-1H-pyrazole-4-boronic acid Price
qrcode